RNA活性化
参照項目

1 2 3 4 5  Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R (November 2006). “Small dsRNAs induce transcriptional activation in human cells”. Proceedings of the National Academy of Sciences of the United States of America 103 (46):  17337–42. doi:10.1073/pnas.0607015103. PMC 1859931. PMID 17085592. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1859931/. [要非一次資料]
↑  Li, Longcheng; Dahiya, Rajvir. "Small Activating RNA Molecules and Methods of Use." U.S. Patent US 8,877,721 filed October 1, 2004, and issued November 4, 2014.
↑  Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR (March 2007). “Activating gene expression in mammalian cells with promoter-targeted duplex RNAs”. Nature Chemical Biology 3 (3):  166–73. doi:10.1038/nchembio860. PMID 17259978.
1 2 3  Turunen MP, Lehtola T, Heinonen SE, Assefa GS, Korpisalo P, Girnary R, Glass CK, Väisänen S, Ylä-Herttuala S (September 2009). “Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy”. Circulation Research 105 (6):  604–9. doi:10.1161/CIRCRESAHA.109.200774. PMID 19696410.
↑  Huang V, Qin Y, Wang J, Wang X, Place RF, Lin G, Lue TF, Li LC (January 2010). Jin, Dong-Yan. ed. “RNAa is conserved in mammalian cells”. PLOS One 5 (1):  e8848. doi:10.1371/journal.pone.0008848. PMC 2809750. PMID 20107511. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2809750/.
1 2  Matsui M, Sakurai F, Elbashir S, Foster DJ, Manoharan M, Corey DR (December 2010). “Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter”. Chemistry & Biology 17 (12):  1344–55. doi:10.1016/j.chembiol.2010.10.009. PMC 3071588. PMID 21168770. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3071588/.
↑  Shibuya K, Fukushima S, Takatsuji H (February 2009). “RNA-directed DNA methylation induces transcriptional activation in plants”. Proceedings of the National Academy of Sciences of the United States of America 106 (5):  1660–5. doi:10.1073/pnas.0809294106. PMC 2629447. PMID 19164525. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629447/.
1 2  Seth M, Shirayama M, Gu W, Ishidate T, Conte D, Mello CC (December 2013). “The C. elegans CSR-1 argonaute pathway counteracts epigenetic silencing to promote germline gene expression”. Developmental Cell 27 (6):  656–63. doi:10.1016/j.devcel.2013.11.014. PMC 3954781. PMID 24360782. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3954781/.
1 2 3  Turner MJ, Jiao AL, Slack FJ (Jan 7, 2014). “Autoregulation of lin-4 microRNA transcription by RNA activation (RNAa) in C. elegans”. Cell Cycle 13 (5):  772–81. doi:10.4161/cc.27679. PMC 3979913. PMID 24398561. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979913/.
↑  Yue X, Schwartz JC, Chu Y, Younger ST, Gagnon KT, Elbashir S, Janowski BA, Corey DR (August 2010). “Transcriptional regulation by small RNAs at sequences downstream from 3' gene termini”. Nature Chemical Biology 6 (8):  621–9. doi:10.1038/nchembio.400. PMC 3909968. PMID 20581822. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909968/.
1 2  Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R (February 2008). “MicroRNA-373 induces expression of genes with complementary promoter sequences”. Proceedings of the National Academy of Sciences of the United States of America 105 (5):  1608–13. doi:10.1073/pnas.0707594105. PMC 2234192. PMID 18227514. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234192/. [要非一次資料]
1 2  Huang V, Place RF, Portnoy V, Wang J, Qi Z, Jia Z, Yu A, Shuman M, Yu J, Li LC (February 2012). “Upregulation of Cyclin B1 by miRNA and its implications in cancer”. Nucleic Acids Research 40 (4):  1695–707. doi:10.1093/nar/gkr934. PMC 3287204. PMID 22053081. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3287204/. [要非一次資料]
1 2  Chu Y, Yue X, Younger ST, Janowski BA, Corey DR (November 2010). “Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter”. Nucleic Acids Research 38 (21):  7736–48. doi:10.1093/nar/gkq648. PMC 2995069. PMID 20675357. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2995069/.
↑  Li, Long-Cheng (2008). “Small RNA-mediated gene activation”. In Morris, Kevin V. RNA and the Regulation of Gene Expression: A Hidden Layer of Complexity. Caister Academic Press. pp. 189–99. ISBN 978-1-904455-25-7. https://books.google.com/books?id=r67Lrf9r9XEC&pg=PA189
1 2  Portnoy V, Huang V, Place RF, Li LC (2011). “Small RNA and transcriptional upregulation”. Wiley Interdisciplinary Reviews: RNA 2 (5):  748–60. doi:10.1002/wrna.90. PMC 3154074. PMID 21823233. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154074/.
↑  Meng X, Jiang Q, Chang N, Wang X, Liu C, Xiong J, Cao H, Liang Z (March 2016). “Small activating RNA binds to the genomic target site in a seed-region-dependent manner”. Nucleic Acids Research 44 (5):  2274–82. doi:10.1093/nar/gkw076. PMC 4797303. PMID 26873922. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797303/.
↑  Portnoy V, Lin SH, Li KH, Burlingame A, Hu ZH, Li H, Li LC (March 2016). “saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription”. Cell Research 26 (3):  320–35. doi:10.1038/cr.2016.22. PMC 4783471. PMID 26902284. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783471/.
↑  Voutila J, Reebye V, Roberts TC, Protopapa P, Andrikakou P, Blakey DC, Habib R, Huber H, Saetrom P, Rossi JJ, Habib NA (December 2017). “Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer”. Molecular Therapy 25 (12):  2705–2714. doi:10.1016/j.ymthe.2017.07.018. PMC 5768526. PMID 28882451. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768526/.
↑  Matsui M, Chu Y, Zhang H, Gagnon KT, Shaikh S, Kuchimanchi S, Manoharan M, Corey DR, Janowski BA (December 2013). “Promoter RNA links transcriptional regulation of inflammatory pathway genes”. Nucleic Acids Research 41 (22):  10086–109. doi:10.1093/nar/gkt777. PMC 3905862. PMID 23999091. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3905862/.
↑  Dharap A, Pokrzywa C, Murali S, Pandi G, Vemuganti R (2013). “MicroRNA miR-324-3p induces promoter-mediated expression of RelA gene”. PLOS One 8 (11):  e79467. doi:10.1371/journal.pone.0079467. PMC 3827167. PMID 24265774. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827167/.
1 2 3  Chaluvally-Raghavan P, Jeong KJ, Pradeep S, Silva AM, Yu S, Liu W, Moss T, Rodriguez-Aguayo C, Zhang D, Ram P, Liu J, Lu Y, Lopez-Berestein G, Calin GA, Sood AK, Mills GB (May 2016). “Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer”. Cell Reports 15 (7):  1493–1504. doi:10.1016/j.celrep.2016.04.034. PMC 4914391. PMID 27160903. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4914391/.
↑  Li S, Wang C, Yu X, Wu H, Hu J, Wang S, Ye Z (January 2017). “miR-3619-5p inhibits prostate cancer cell growth by activating CDKN1A expression”. Oncology Reports 37 (1):  241–248. doi:10.3892/or.2016.5250. PMID 27878260.
↑  Xiao M, Li J, Li W, Wang Y, Wu F, Xi Y, Zhang L, Ding C, Luo H, Li Y, Peng L, Zhao L, Peng S, Xiao Y, Dong S, Cao J, Yu W (October 2017). “MicroRNAs activate gene transcription epigenetically as an enhancer trigger”. RNA Biology 14 (10):  1326–1334. doi:10.1080/15476286.2015.1112487. PMC 5711461. PMID 26853707. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711461/.
↑  Vaschetto LM (April 2018). “miRNA activation is an endogenous gene expression pathway”. RNA Biology:  1–3. doi:10.1080/15476286.2018.1451722. PMC 6152443. PMID 29537927. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152443/.
↑  Conine CC, Moresco JJ, Gu W, Shirayama M, Conte D, Yates JR, Mello CC (December 2013). “Argonautes promote male fertility and provide a paternal memory of germline gene expression in C. elegans”. Cell 155 (7):  1532–44. doi:10.1016/j.cell.2013.11.032. PMC 3924572. PMID 24360276. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924572/.
↑  Wedeles CJ, Wu MZ, Claycomb JM (December 2013). “Protection of germline gene expression by the C. elegans Argonaute CSR-1”. Developmental Cell 27 (6):  664–71. doi:10.1016/j.devcel.2013.11.016. PMID 24360783.
↑  Paugh SW, Coss DR, Bao J, Laudermilk LT, Grace CR, Ferreira AM, Waddell MB, Ridout G, Naeve D, Leuze M, LoCascio PF, Panetta JC, Wilkinson MR, Pui CH, Naeve CW, Uberbacher EC, Bonten EJ, Evans WE (February 2016). “MicroRNAs Form Triplexes with Double Stranded DNA at Sequence-Specific Binding Sites; a Eukaryotic Mechanism via which microRNAs Could Directly Alter Gene Expression”. PLoS Computational Biology 12 (2):  e1004744. doi:10.1371/journal.pcbi.1004744. PMC 4742280. PMID 26844769. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742280/.
↑  Huang V, Zheng J, Qi Z, Wang J, Place RF, Yu J, Li H, Li LC (2013). “Ago1 Interacts with RNA polymerase II and binds to the promoters of actively transcribed genes in human cancer cells”. PLoS Genetics 9 (9):  e1003821. doi:10.1371/journal.pgen.1003821. PMC 3784563. PMID 24086155. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784563/.
↑  Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, Huang J, Li LC (December 2010). “Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration”. Cancer Research 70 (24):  10182–91. doi:10.1158/0008-5472.CAN-10-2414. PMC 3076047. PMID 21159640. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076047/.
↑  Chen R, Wang T, Rao K, Yang J, Zhang S, Wang S, Liu J, Ye Z (October 2011). “Up-regulation of VEGF by small activator RNA in human corpus cavernosum smooth muscle cells”. The Journal of Sexual Medicine 8 (10):  2773–80. doi:10.1111/j.1743-6109.2011.02412.x. PMID 21819543.
↑  Kang MR, Yang G, Place RF, Charisse K, Epstein-Barash H, Manoharan M, Li LC (October 2012). “Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth”. Cancer Research 72 (19):  5069–79. doi:10.1158/0008-5472.can-12-1871. PMID 22869584.
↑  Place RF, Wang J, Noonan EJ, Meyers R, Manoharan M, Charisse K, Duncan R, Huang V, Wang X, Li LC (March 2012). “Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression”. Molecular Therapy. Nucleic Acids 1 (3):  e15. doi:10.1038/mtna.2012.5. PMC 3381590. PMID 23343884. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3381590/.
↑  Yoon S, Huang KW, Reebye V, Mintz P, Tien YW, Lai HS, Sætrom P, Reccia I, Swiderski P, Armstrong B, Jozwiak A, Spalding D, Jiao L, Habib N, Rossi JJ (June 2016). “Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo”. Molecular Therapy 24 (6):  1106–1116. doi:10.1038/mt.2016.60. PMC 4923325. PMID 26983359. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4923325/.
↑  Huan H, Wen X, Chen X, Wu L, Liu W, Habib NA, Bie P, Xia F (2016-01-01). “C/EBPα Short-Activating RNA Suppresses Metastasis of Hepatocellular Carcinoma through Inhibiting EGFR/β-Catenin Signaling Mediated EMT”. PLOS One 11 (4):  e0153117. doi:10.1371/journal.pone.0153117. PMC 4822802. PMID 27050434. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822802/.
↑  Li C, Jiang W, Hu Q, Li LC, Dong L, Chen R, Zhang Y, Tang Y, Thrasher JB, Liu CB, Li B (April 2016). “Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis”. Oncotarget 7 (16):  22893–910. doi:10.18632/oncotarget.8290. PMC 5008410. PMID 27014974. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008410/.
↑  Reebye V, Huang KW, Lin V, Jarvis S, Cutilas P, Dorman S, Ciriello S, Andrikakou P, Voutila J, Saetrom P, Mintz PJ, Reccia I, Rossi JJ, Huber H, Habib R, Kostomitsopoulos N, Blakey DC, Habib NA (June 2018). “Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer”. Oncogene 37 (24):  3216–3228. doi:10.1038/s41388-018-0126-2. PMC 6013054. PMID 29511346. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013054/.
↑  “MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Patients with Liver Cancer | Business Wire”. www.businesswire.com. 2016年6月6日閲覧。
↑  “First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer - Full Text View - ClinicalTrials.gov”. clinicaltrials.gov. 2016年6月6日閲覧。